- Home
- OCEAW vs CENX Comparison
OCEAW vs CENX Comparison
Compare OCEAW & CENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCEAW
- CENX
- Stock Information
- Founded
- OCEAW N/A
- CENX 1995
- Country
- OCEAW United States
- CENX United States
- Employees
- OCEAW 7
- CENX N/A
- Industry
- OCEAW Biotechnology: Pharmaceutical Preparations
- CENX Aluminum
- Sector
- OCEAW Health Care
- CENX Industrials
- Exchange
- OCEAW Nasdaq
- CENX Nasdaq
- Market Cap
- OCEAW N/A
- CENX N/A
- IPO Year
- OCEAW 2021
- CENX 1996
- Fundamental
- Price
- OCEAW $0.02
- CENX $19.41
- Analyst Decision
- OCEAW
- CENX Strong Buy
- Analyst Count
- OCEAW 0
- CENX 3
- Target Price
- OCEAW N/A
- CENX $23.00
- AVG Volume (30 Days)
- OCEAW N/A
- CENX 2.2M
- Earning Date
- OCEAW N/A
- CENX 04-30-2025
- Dividend Yield
- OCEAW N/A
- CENX N/A
- EPS Growth
- OCEAW N/A
- CENX N/A
- EPS
- OCEAW N/A
- CENX 3.27
- Revenue
- OCEAW N/A
- CENX $2,220,300,000.00
- Revenue This Year
- OCEAW N/A
- CENX $11.16
- Revenue Next Year
- OCEAW N/A
- CENX $3.93
- P/E Ratio
- OCEAW N/A
- CENX $5.89
- Revenue Growth
- OCEAW N/A
- CENX 1.60
- 52 Week Low
- OCEAW N/A
- CENX $11.35
- 52 Week High
- OCEAW N/A
- CENX $25.39
- Technical
- Relative Strength Index (RSI)
- OCEAW N/A
- CENX 50.17
- Support Level
- OCEAW N/A
- CENX $16.45
- Resistance Level
- OCEAW N/A
- CENX $19.35
- Average True Range (ATR)
- OCEAW 0.00
- CENX 1.54
- MACD
- OCEAW 0.00
- CENX -0.10
- Stochastic Oscillator
- OCEAW 0.00
- CENX 58.93
About OCEAW Ocean Biomediacal Inc.
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.